Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Cfoofme, ... About VIP in Lung Injury
Vasoactive Intestinal Polypeptide (VIP) was first characterized by the late Dr. Sami Said in the 1970s. Although first identified in the intestinal tract, VIP is now known to be manufactured throughout the body and to be heavily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.

https://www.biospace.com/article/releases/relief-therapeutics-announces-filing-of-ind-for-phase-2-3-clinical-trial-of-inhaled-rlf-100-targeting-early-covid-19-lung-injury/

Best